Do you want to read an article? Please log in or register.
Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
Lipid-Lowering Drugs
Related content
Lipid-Lowering Drugs
Efficacy of lipid reduction with DALI and MONET
Atheroscler Suppl.
Ramlow W, Röseler E, Heigl F, Spitthöver R, Ringel J, Schmitz G, Heinzler R, Abdul-Rahman N, Leistikow F, Himmelsbach F, Schettler V, Pham J, Kozik-Jaromin J
doi: 10.1016/
Lipid-Lowering Drugs
Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials
Cardiovasc Drugs Ther.
Bays HE, Rosenson RS, Baccara-Dinet MT, Louie MJ, Thompson D, Hovingh GK
doi: 10.1007/s10557-018-6784-z.
RECOMMENDED
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials
Circulation.
Marston NA, Giugliano RP, Im K, Silverman MG, O'Donoghue ML, Wiviott SD, Ference BA, Sabatine MS
doi: 10.1161/
Lipid-Lowering Drugs
Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment
Eur Heart J.
Stiekema LCA, Stroes ESG, Verweij SL, Kassahun H, Chen L, Wasserman SM, Sabatine MS, Mani V, Fayad ZA
doi: 10.1093/eurheartj/ehy862.
Myocardial Infarction
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
Lancet.
Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ; CANTOS Trial Group
doi: 10.1016/
Lipid-Lowering Drugs
An innovative lipid-lowering approach to enhance attainment of low-density lipoprotein cholesterol goals
Eur Heart J Acute Cardiovasc Care.
Buonvino C, Chopard R, Guillon B, Puymirat E, Farnier M, Ferrières J, Krempf M, Bruckert E, Meneveau N, Schiele F
doi: 10.1177/2048872620912639.
Lipid-Lowering Drugs
Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome and without diabetes: Pooled data from 10 phase 3 trials
Diabetes Obes Metab.
Henry RR, Müller-Wieland D, Taub PR, Bujas-Bobanovic M, Louie MJ, Letierce A, Ginsberg HN
doi: 10.1111/dom.13273.
RECOMMENDED
Heart, Artery and Coronary DiseasesLipid-Lowering Drugs
Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies
★ 2
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Atherosclerosis.
Pasta A, Cremonini AL, Formisano E, Fresa R, Bertolini S, Pisciotta L
doi: 10.1016/j.atherosclerosis.2020.07.006.
Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesLipid-Lowering Drugs
Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease
JAMA Cardiol.
Cannon CP, Khan I, Klimchak AC, Reynolds MR, Sanchez RJ, Sasiela WJ
doi: 10.1001/